Elecoglipron

Oral SMD GLP-1 RA · AstraZeneca

Top dose
75 mg
Weight loss
-11.8%
at week 36 · efficacy
AE discontinuation
4.1%
Status
phase 2

Weight loss trajectory #

Weight loss trajectory for Elecoglipron 75 mg over 36 weeks in the VISTA trial.

Pivotal trial #

Trial
VISTA
Indication
obesity (no T2D)
Duration
36 weeks
ClinicalTrials.gov
NCT06579092
Sponsor
AstraZeneca

Notes #

Phase shown reflects the DATA: the -11.8% is from Phase 2b. The Ph3 Eluminate program (NCT07662044/NCT07662213/NCT07664553) is not-yet-recruiting (2028 completion). Phase 2; no plateau by wk 36. Phase 3 EMBOLD program announced (EU CT 2025-524688-19). No food/water restriction. AE-led disc 2/49 (4.1%) at 75 mg once-daily titration top dose (VISTA Davies Lancet 2026; AZD5004 film-coated tablet once daily per NCT06579092).